Cancer Management and Research最新文献

{"title":"A Metabolic Cluster-Derived Risk Model for Prognostic Stratification, Immunometabolic Profiling, and Therapeutic Sensitivity Prediction in Prostate Cancer.","authors":"Wensi Liu, Cong Wang, Tao Su, Jinjin Zhang, Yingjie Wu","doi":"10.2147/CMAR.S640203","DOIUrl":"10.2147/CMAR.S640203","url":null,"abstract":"<p><strong>Purpose: </strong>Metabolic reprogramming is a hallmark of prostate cancer; however, the clinical utility of metabolism-related genes for prognostic stratification remains limited.</p><p><strong>Patients and methods: </strong>Prostate cancer patients from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases were stratified into metabolism-associated clusters based on metabolism-related gene expression. Genes differentially expressed between clusters were used to construct a prognostic risk model via least absolute shrinkage and selection operator (LASSO) regression. Associations with clinicopathological features, genomic alterations, metabolic activity, immune status, and therapeutic response were systematically evaluated. Computational analyses included tumor immune dysfunction and exclusion (TIDE) and the immunophenoscore for predicting immunotherapy response, pRRophetic and CellMiner for assessing drug sensitivity, and the Connectivity Map for screening candidate compounds. Exploratory assessments were performed using immunohistochemistry (IHC) in a 20-patient cohort with follow-up data and quantitative polymerase chain reaction (qPCR) in an independent 14-patient cohort.</p><p><strong>Results: </strong>Two metabolism-associated clusters with distinct survival outcomes and molecular features were identified. A three-gene signature stratified patients into high- and low-risk groups, with the high-risk group showing poorer survival, greater tumor aggressiveness, elevated tumor mutational burden and microsatellite instability, and enhanced metabolic pathway activity. This group also exhibited an immunosuppressive microenvironment and was predicted to have reduced responsiveness to some immunotherapies and endocrine therapies, along with increased resistance to specific chemotherapeutic agents. In silico analyses suggested several candidate small molecules for further evaluation in the high-risk group. The IHC- and qPCR-based exploratory experiments showed associations between the derived scores and clinicopathological features, providing preliminary support for the transcriptomic signature.</p><p><strong>Conclusion: </strong>This metabolic cluster-derived three-gene model may support prognostic stratification and characterization of immunometabolic heterogeneity in prostate cancer. The observed associations between metabolic heterogeneity and computationally predicted therapeutic sensitivity provide a rationale for further investigation of potential treatment strategies.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"18 ","pages":"640203"},"PeriodicalIF":2.6,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13674457/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149215022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Holistic Framework for Cervical Cancer Screening and Risk Stratification: Integrating Etiology, Morphology, Epigenetics, and Microecology.","authors":"Hong Tao, Xiaozhu Pei, Hongtao Li, Hua Xie, Jincheng Fang","doi":"10.2147/CMAR.S633709","DOIUrl":"https://doi.org/10.2147/CMAR.S633709","url":null,"abstract":"<p><p>Cervical cancer (CC) remains a major global health burden despite being highly preventable through early detection. Current screening strategies, predominantly high-risk human papillomavirus (HR-HPV) testing and liquid-based cytology (LBC), have limited specificity, leading to unnecessary colposcopic referrals and overtreatment. This narrative review proposes a conceptual holistic screening framework-termed HADm-that integrates four complementary pillars into a unified risk stratification system: (1) Etiology (HR-HPV genotyping), (2) Morphology (artificial intelligence-assisted LBC, Ai-LBC), (3) Epigenetics (DNA methylation [DNAm] biomarkers, with PAX1 methylation as an example), and (4) Microecology (genital pathogens and vaginal microbiota). Persistent HR-HPV infection is the primary etiological factor, while disease progression is modulated by host epigenetic alterations and the local microenvironment. DNAm markers may serve as molecular indicators of malignant transformation and have shown high specificity for cervical intraepithelial neoplasia grade 2 or worse (CIN2+) and grade 3 or worse (CIN3+) among human papillomavirus (HPV)-positive women in some studies. Ai-LBC may improve both sensitivity and standardization of morphological interpretation, whereas genital pathogen and microbiota may help explain persistent HPV infection and chronic inflammation. However, evidence for the combined HADm framework remains limited, and prospective multicenter validation is lacking. This framework represents a shift from single-analyte testing toward integrated risk assessment, but its incremental clinical value, cost-effectiveness, and feasibility in low- and middle-income countries require rigorous evaluation. If validated, HADm may support precise risk stratification, individualized follow-up, and more efficient resource allocation, aligning with the World Health Organization (WHO) global goal of accelerating CC elimination by 2030.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"18 ","pages":"633709"},"PeriodicalIF":2.6,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13656901/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149178871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Precision Management of Tumor-Associated Fever: From Classification to Targeted Intervention.","authors":"Wen Yang, Liman Wang, Yuwei Liu, Shaofan Zhang, Gao Tan, Xiaoli Liu","doi":"10.2147/CMAR.S614478","DOIUrl":"https://doi.org/10.2147/CMAR.S614478","url":null,"abstract":"<p><p>Tumor-associated fever (TAF) is a common clinical complication in patients with malignant tumors, encompassing neoplastic fever directly attributable to the malignancy itself and secondary fever induced by anticancer treatments. Its pathogenesis is complex, clinical differentiation remains challenging, and it exerts a dual impact on tumor progression and therapeutic response. In the context of advancing precision medicine, a conceptual framework integrating \"differential classification-mechanism orientation-targeted intervention\" has been proposed to guide the future management of TAF, shifting from the traditional empirical approach. This review systematically outlines the evolution of TAF definitions, epidemiological heterogeneity, multidimensional differential diagnosis strategies, and a three-dimensional subtyping framework integrating etiological mechanisms, molecular characteristics, and clinical phenotypes. We focus on elucidating the pyrogenic mechanisms centered on the IL-6/JAK/STAT3 axis and the subtype-specific molecular underpinnings, and comprehensively summarize the refined application of traditional non-steroidal anti-inflammatory drugs, targeted therapies (including cytokine antagonists, JAK inhibitors, and HSP inhibitors), and emerging interventions (natural bioactive compounds and intravascular temperature control), along with their levels of evidence. This review also addresses key bottlenecks hindering clinical translation-namely, the lack of highly specific diagnostic biomarkers, the scarcity of high-level evidence for targeted interventions, and the absence of a stratified decision-making framework for the \"double-edged sword\" effects of antipyretic therapy-and proposes corresponding solutions. Finally, we discuss the potential of integrating artificial intelligence and multi-omics technologies into personalized, whole-process TAF management, emphasizing that future efforts should rely on prospective disease-specific cohorts and randomized controlled trials to facilitate the transition from empirical symptomatic management to data-driven precision intervention.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"18 ","pages":"614478"},"PeriodicalIF":2.6,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13656914/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149179454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endobronchial Pulmonary Typical Carcinoid Tumors in Young Adults: A Three-Case Series Highlighting Obstructive Complications and Surgical Outcomes.","authors":"Issam Alkhayer, Mohammad Alaa Aldakak, Youssef Abbas","doi":"10.2147/CMAR.S645295","DOIUrl":"https://doi.org/10.2147/CMAR.S645295","url":null,"abstract":"<p><strong>Background: </strong>Typical pulmonary carcinoid tumors are uncommon, well-differentiated neuroendocrine neoplasms that often arise in the central airways and may present with nonspecific obstruction-related respiratory symptoms, resulting in delayed diagnosis. We report a three-case series of endobronchial typical pulmonary carcinoid tumors in young adults, highlighting their variable obstructive complications and surgical outcomes.</p><p><strong>Methods: </strong>This retrospective case series included three consecutive patients managed at a tertiary university hospital in Syria. Clinical presentation, imaging, bronchoscopic findings, operative details, histopathology, and follow-up data were obtained from medical records. All patients had histopathologically confirmed typical pulmonary carcinoid tumors with central/endobronchial involvement and underwent definitive surgical resection. Patient identifiers were removed, and written informed consent for publication and use of accompanying images was obtained.</p><p><strong>Results: </strong>The patients were 23-35 years old and presented with different manifestations of central airway obstruction: chronic productive cough (Case 1), post-obstructive suppuration with lung abscesses (Case 2), and recurrent hemoptysis with atelectatic/post-obstructive changes (Case 3). Bronchoscopy demonstrated obstructing endobronchial lesions in all three cases, and histopathology confirmed typical carcinoid tumors with low mitotic activity and no necrosis. Case 1 underwent right middle and lower bilobectomy with systematic mediastinal lymph node dissection for a large tumor staged T4N1M0. Cases 2 and 3 underwent left lower lobectomy; in Case 3, this included bronchial segment resection with primary closure and mediastinal lymph node dissection. Resection margins were negative in all cases, and mediastinal nodes were negative in Cases 2 and 3. No adjuvant therapy was administered. Follow-up showed no recurrence approximately 4.5 years after surgery in Case 1, clinical stability at one month in Case 2, and stable chest imaging at six months in Case 3.</p><p><strong>Conclusion: </strong>Endobronchial typical pulmonary carcinoid tumors in young adults can produce diverse obstruction-related complications, including chronic cough, post-obstructive suppuration, and hemoptysis with atelectatic changes. Timely airway evaluation and complete surgical resection with appropriate nodal assessment can achieve favorable outcomes, including in locally advanced disease when complete resection is feasible.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"18 ","pages":"645295"},"PeriodicalIF":2.6,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13659649/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149179063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Distinguishing Second Primary Müllerian Cancer from Breast Cancer Recurrence: Immunohistochemical Pitfalls and a Proposed Diagnostic Algorithm: A Case Report and Literature Review.","authors":"Fangjian Zhou, Huihui Chen, Jili Qiu, Xi Guo, Haoying Liu, Licong Chen, Dan Li, Sifeng Tao, Fu Zhang","doi":"10.2147/CMAR.S630391","DOIUrl":"https://doi.org/10.2147/CMAR.S630391","url":null,"abstract":"<p><p>Distinguishing a second primary Müllerian high‑grade serous carcinoma (HGSC) from metastatic breast cancer in survivors is a diagnostic challenge, especially when peritoneal carcinomatosis occurs without an adnexal mass. We report a 48‑year‑old woman with prior luminal B breast cancer who presented with liver and abdominal wall nodules. Initially misdiagnosed as breast cancer recurrence based on limited immunohistochemistry (IHC), she received 12 months of ineffective therapy. Repeat biopsy with an extended panel (PAX8+, WT1+, p53 mutant‑type, GATA3 weak/partial, GCDFP‑15-) established primary HGSC. A literature review of comparative IHC studies identifies key pitfalls: TRPS1 is positive in 40-47% of HGSCs in large cohorts, with some series reporting up to 70%; PAX8 with the MRQ50 clone is falsely positive in 40% of triple‑negative breast cancers (TNBC); and GATA3 shows weak/focal positivity in 6-13% of HGSCs. A proposed six‑marker panel (PAX8, WT1, GATA3, p53, GCDFP‑15, TRPS1) is recommended to prevent misdiagnosis and expedite appropriate platinum‑based therapy and cytoreductive surgery.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"18 ","pages":"630391"},"PeriodicalIF":2.6,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13656922/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149178835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Peri-Neoadjuvant Chemotherapy Hemoglobin, Albumin, Lymphocyte, and Platelet Score with Complete Gross Resection at Interval Debulking Surgery in Advanced Ovarian Cancer: An Exploratory Retrospective Cohort Study.","authors":"Hao Su, Mingle Tian, Yongxue Wang, Yuan Li, Ying Jin, Ying Shan, Fengzhi Feng, Tao Wang","doi":"10.2147/CMAR.S640970","DOIUrl":"https://doi.org/10.2147/CMAR.S640970","url":null,"abstract":"<p><strong>Introduction: </strong>Complete gross resection (CGR) at interval debulking surgery (IDS) is a critical surgical endpoint in ovarian cancer, but its likelihood remains difficult to estimate before surgery in patients treated with neoadjuvant chemotherapy (NACT). The hemoglobin, albumin, lymphocyte, and platelet (HALP) score integrates nutritional, inflammatory, immune, and anemia-related status, but its association with CGR after NACT remains unclear. This study evaluated the association of peri-NACT HALP with CGR at IDS.</p><p><strong>Methods: </strong>We retrospectively analyzed 239 patients with advanced high-grade serous ovarian cancer who received platinum-based NACT followed by IDS. HALP was calculated before NACT and before IDS, and HALP difference was defined as the latter minus the former. The ability of HALP-related indices to distinguish CGR was examined using receiver operating characteristic analyses and logistic regression models. Exploratory analyses further examined KELIM score, chemotherapy response score, and survival outcomes in relation to these indices.</p><p><strong>Results: </strong>Compared with the non-CGR group, the CGR group showed higher HALP at both sampling points and a larger peri-NACT difference. The area under the curve was 0.761 for HALP before NACT, 0.816 for HALP before IDS, and 0.593 for HALP difference. In multivariate analysis, HALP before NACT >19.3 and HALP before IDS >33.4 remained independently associated with lower odds of non-CGR, whereas HALP difference did not. Combined pre/post HALP status further stratified CGR rates. Exploratory analyses also suggested associations between HALP-related indices and NACT response indicators and survival outcomes.</p><p><strong>Conclusion: </strong>HALP before NACT and before IDS were associated with CGR after NACT, whereas HALP difference showed limited discriminatory performance. These exploratory associations require further external validation.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"18 ","pages":"640970"},"PeriodicalIF":2.6,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13656913/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149178911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MSCT Manifestations and Quantitative Dynamic Evolution of Lung Cancer Associated with Cystic Airspaces: A Retrospective Analysis of 102 Cases with Emphasis on Adenocarcinoma.","authors":"Xiaoqin Luo, Shan Lan, Chengwen Tong","doi":"10.2147/CMAR.S611348","DOIUrl":"https://doi.org/10.2147/CMAR.S611348","url":null,"abstract":"<p><strong>Objective: </strong>Cystic lung cancer (CLC) refers to lung cancer associated with cystic airspaces. This study characterized the Multi-Slice Computed Tomography (MSCT) features of CLC, with subtype-specific and longitudinal analyses restricted to adenocarcinoma cases.</p><p><strong>Methods: </strong>We retrospectively analyzed 102 patients with pathologically confirmed CLC at Renmin Hospital (2018-2025). Of these, 94 (92.2%) had adenocarcinoma, classified per the IASLC/ATS/ERS system; MSCT features were compared across subtypes using Chi-square tests. The 8 non-adenocarcinoma cases were described separately. A subgroup of 45 patients with serial CT (≥3-month interval), all with adenocarcinoma, was assessed for longitudinal changes.</p><p><strong>Results: </strong>The cohort included 64 males and 38 females (mean age 64.2 ± 11.7 years). Histology showed adenocarcinoma in 94 cases (42 acinar, 28 lepidic, 14 papillary, 10 solid/micropapillary), 6 squamous cell carcinomas, and 2 sarcomatoid carcinomas. In the 8 non-adenocarcinoma cases, irregular shape and uneven wall thickness each occurred in 7/8 (87.5%), wall nodules in 6/8 (75.0%). Overall, 78/102 (76.5%) lesions were irregular and 74/102 (72.5%) showed uneven wall thickness. In adenocarcinoma, uneven wall thickness (P = 0.008) and internal septations (P = 0.001) were associated with lepidic/acinar subtypes, whereas solid/micropapillary subtypes showed thicker walls and more frequent wall nodules. In the dynamic group (n=45), solid-component growth rate (1.21 ± 0.29 mm/month) exceeded cystic-airspace growth (0.31 ± 0.11 mm/month, P < 0.001) and correlated with follow-up interval (r = 0.81, P < 0.001). In multivariable analysis restricted to adenocarcinoma, wall thickness >4 mm was independently associated with solid/micropapillary subtypes (OR = 5.78, 95% CI 1.28-26.02, P = 0.022); other variables were nonsignificant trends.</p><p><strong>Conclusion: </strong>CLC exhibits MSCT features that correlate with adenocarcinoma subtypes, with progressive solid-component growth over time. These observations are descriptive; prospective multicenter studies including benign cystic lesions and more non-adenocarcinoma cases are needed before diagnostic application.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"18 ","pages":"611348"},"PeriodicalIF":2.6,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13654261/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149167222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Scleroderma-Like Skin Changes and Multifocal Muscle Thickening in a Patient with Diffuse Large B-Cell Lymphoma: A Case Report.","authors":"Hussam Aldeen Mansour, Alaa Senjab, Nawwar Fallouh, Balkis Hamid Al Abdul Rahman, Zeina Makhlouf, Hamza Shammout, Khaldoun Almhanna, Salwa Alcheikh","doi":"10.2147/CMAR.S642864","DOIUrl":"https://doi.org/10.2147/CMAR.S642864","url":null,"abstract":"<p><strong>Background: </strong>Paraneoplastic rheumatic manifestations may precede the diagnosis of an occult malignancy and closely mimic primary autoimmune connective-tissue diseases. Scleroderma-like manifestations have rarely been reported in association with lymphoid malignancies, including diffuse large B-cell lymphoma (DLBCL).</p><p><strong>Case presentation: </strong>A 47-year-old woman presented with progressive skin thickening, difficulty walking, reduced appetite, and weight loss. She had been diagnosed with scleroderma by an outside physician in early 2024 and had been treated with methotrexate 15 mg once weekly. Physical examination revealed facial skin tightening, sclerodactyly, skin induration extending to the wrists and elbows, and asymmetric thickening of the right neck, forearm, and thigh muscles. Pruritic migratory annular plaques were observed on the trunk and resolved spontaneously within two weeks, clinically suggesting an erythema annulare centrifugum-like eruption. Raynaud phenomenon was absent, antinuclear antibody testing was negative, and cervical and axillary lymphadenopathy was present. Computed tomography demonstrated multiple destructive osteolytic lesions in the lumbar vertebrae. Neck magnetic resonance imaging showed edema-like T2 hyperintensity involving the sternocleidomastoid muscle and adjacent tissues without contrast enhancement. Biopsy of a vertebral lesion revealed DLBCL, with tumor cells positive for leukocyte common antigen and CD20 and a Ki-67 proliferation index of approximately 80%. The patient was started on standard first-line R-CHOP immunochemotherapy but died in the intensive care unit after the first treatment administration, precluding assessment of treatment response and longer-term follow-up.</p><p><strong>Conclusion: </strong>This case illustrates an unusual presentation of DLBCL accompanied by scleroderma-like cutaneous changes, multifocal muscle thickening, and an annular eruption. The simultaneous absence of Raynaud phenomenon and antinuclear antibodies, together with constitutional symptoms, lymphadenopathy, asymmetric soft-tissue abnormalities, and destructive bone lesions, should prompt reconsideration of presumed systemic sclerosis and evaluation for an underlying malignancy. Although a paraneoplastic association was strongly suspected, it could not be confirmed because the patient died after the first treatment administration, precluding assessment of the rheumatic manifestations after lymphoma-directed therapy.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"18 ","pages":"642864"},"PeriodicalIF":2.6,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13654266/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149166095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond Treatment, Understanding the Holistic Needs of Cancer Patients and Family Caregivers: A Qualitative Study from the Perspectives of Patients, Family Caregivers, and Health Care Providers.","authors":"Shima Yadegar Tirandaz, Leila Valizadeh, Vahid Zamanzadeh, Maryam Rassouli, Mohammad Esmaeil Akbari","doi":"10.2147/CMAR.S637364","DOIUrl":"10.2147/CMAR.S637364","url":null,"abstract":"<p><strong>Introduction: </strong>Cancer is a complex disease and can affect the integrity of individuals, their health dimensions and quality of life, and their families, leading to changes in priorities and the emergence of new needs. Therefore, the first step in providing quality care, improving survival, and planning treatment, care, and support services is to identify and meet the needs of this group of patients.</p><p><strong>Research objective: </strong>This study aimed to identify the holistic needs of cancer patients and their family caregivers from the perspectives of patients, family caregivers, and cancer care providers.</p><p><strong>Materials and methods: </strong>This qualitative study was conducted using conventional content analysis. Data were collected through in-depth, semi-structured, and face-to-face interviews with 8 patients, 9 family caregivers, and 14 cancer care providers, a total of 31 participants who were selected using a purposeful sampling method. Data were analyzed using conventional content analysis by Graneheim and Lundman and coded with MAXQDA-10 software. Data Rigor was evaluated using Lincoln & Guba criteria.</p><p><strong>Findings: </strong>Analysis of the interviews revealed 9 categories and 22 subcategories for the needs. The categories included informational needs (2 subcategories), financial (2 subcategories), physical (2 subcategories), psychosocial (4 subcategories), spiritual (2 subcategories), family caregivers' needs (2 subcategories), access to services (3 subcategories), standard care (3 subcategories), and continuity of care (2 subcategories).</p><p><strong>Conclusion: </strong>Cancer patients and their family caregivers have many types of needs that extend beyond treatment-related issues. By integrating the perspectives of patients, family caregivers, and cancer care providers, this study provides a comprehensive understanding of cancer-related needs that allows healthcare providers and health policymakers to take positive steps to provide optimal patient- and family-centered care for these patients.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"18 ","pages":"637364"},"PeriodicalIF":2.6,"publicationDate":"2026-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13644720/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149135096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Retrospective Cohort Analysis of Risk Factors for Lymph Node Metastasis in Multiple Primary Lung Cancer with 215 Cases.","authors":"Tao Shen, Sisi Yang, Shengshan Xu, Zhichao Lin, Dongxi Zhang, Yongwen Ke, Zhuowen Chen, Zhuming Lu","doi":"10.2147/CMAR.S622808","DOIUrl":"10.2147/CMAR.S622808","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the pattern of lymph node metastasis (LNM) in multiple primary lung cancers (MPLC) and related influencing factors.</p><p><strong>Methods: </strong>We retrospectively analyzed the lymph node status of 215 patients with MPLC diagnosed by pathological and imaging examinations at Guangdong Jiangmen Central Hospital between January 2015 and December 2021, evaluating the relationship between age, smoking history, tumor markers, primary lesion diameter (PLD), pathological type, lesion location and LNM.</p><p><strong>Results: </strong>There were no statistically significant differences in age, smoking history, Cyfra 21-1, tumor location, or the number of lesions between groups regarding LNM. Binary logistic regression analysis demonstrated that CEA (OR=0.129, 95% CI=0.039-0.426), PLD (OR=0.377, 95% CI=0.207-0.689), and pathological type (OR=1.303, 95% CI=1.019-1.665) were independent risk factors. ROC analysis demonstrated that CEA and PLD could serve as potential predictive indicators for LNM, but a comprehensive model integrating multiple risk factors provided higher clinical predictive value. The LNM rate was significantly higher in patients with CEA > 5ng/mL than those with CEA ≤5ng/mL (<i>P</i> <0.05) and was associated with a poorer prognosis. LNM rates and prognosis varied across pathological subtypes (<i>P</i> <0.05), with higher incidences observed in Solid Predominant Adenocarcinoma (SPA), Micropapillary Predominant Adenocarcinoma (MPA), and Acinar Predominant Adenocarcinoma (ACI), while no LNM occurred in Papillary Predominant Adenocarcinoma (PAP), Lepidic Predominant Adenocarcinoma (LPA), or Minimally Invasive Adenocarcinoma (MIA). The incidence of LNM is positively correlated with prognosis. The LNM rate was positively correlated with PLD.</p><p><strong>Conclusion: </strong>LNM in MPLC is associated with CEA, PLD and pathological type. Systematic lymph node dissection may be considered appropriate when PLD >20mm, CEA >5ng/mL, or when the tumor is SPA or MPA, whereas systematic lymph node sampling may be considered for ACI and other pathological types. These findings provide a preliminary framework that requires prospective validation.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"18 ","pages":"622808"},"PeriodicalIF":2.6,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13641107/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}